文献速递肿瘤 PET/CT核素与放射性配体治疗

前列腺癌淋巴结评估:光谱探测器CT碘定量与PSMA PET/CT的相关性

Lymph Node Assessment in Prostate Cancer: Evaluation of Iodine Quantification With Spectral Detector CT in Correlation to PSMA PET/CT.
PubMed 文献 · Clin Nucl Med · 2021-01-01

PSMA PET/CT诊断的转移淋巴结IC高于良性淋巴结(1.9±0.6 mg/mL vs 1.5±0.5 mg/mL,P<0.05),AUC为0.72,灵敏度/特异度81.3%/58.5%。IC与SUVmax仅呈弱正相关(rs=0.25,P<0.001),提示PSMA PET/CT仍是淋巴结转移检测的重要参考影像。

要点

  • PSMA PET/CT诊断的转移淋巴结SDCT碘浓度更高,但数据重叠明显
  • IC诊断淋巴结转移的AUC为0.72,灵敏度81.3%、特异度58.5%
  • IC与SUVmax仅弱相关(rs=0.25),PSMA PET/CT参考价值更重要

核心结论

  • SDCT碘浓度在前列腺癌PSMA PET/CT诊断的转移淋巴结中升高,但良恶性数据重叠明显,鉴别能力有限。
  • IC与SUVmax仅呈弱正相关,PSMA PET/CT仍是前列腺癌淋巴结转移检测的重要参考影像模态。

研究设计与样本

  • 患者接受PSMA PET/CT及门静脉期腹部SDCT检查,仅纳入淋巴结大小稳定且PSA水平可比的扫描对。
  • 基于感兴趣区获取SDCT碘图碘浓度及PSMA PET/CT超高分辨率重建的SUVmax。

主要发现

  • PSMA PET/CT诊断的转移淋巴结IC高于非转移淋巴结(1.9±0.6 mg/mL vs 1.5±0.5 mg/mL,P<0.05)。
  • IC诊断转移淋巴结的AUC为0.72,灵敏度/特异度为81.3%/58.5%。
  • 转移淋巴结平均短轴直径大于非转移淋巴结(6.9±3.6 mm vs 5.3±1.3 mm,P<0.05)。
  • 以短轴直径1 cm为阈值,灵敏度/特异度为12.8%/99.0%。
  • SUVmax与IC呈显著但弱正相关(rs=0.25;P<0.001)。

关键数值与推荐

  • 转移淋巴结IC为1.9±0.6 mg/mL,非转移淋巴结为1.5±0.5 mg/mL(P<0.05)。
  • IC诊断淋巴结转移的AUC为0.72,灵敏度81.3%、特异度58.5%。
  • 短轴直径1 cm阈值的灵敏度为12.8%、特异度为99.0%。
  • SUVmax与IC的相关系数rs=0.25(P<0.001)。

临床怎么用

  • SDCT碘浓度可作为PSMA PET/CT之外的辅助信息,但单独用于淋巴结良恶性鉴别时数据重叠明显,需谨慎解读。
  • PSMA PET/CT仍是前列腺癌淋巴结转移检测的重要参考影像模态,SDCT碘定量不能替代其作用。

局限性

  • 仅纳入淋巴结大小稳定且PSA水平可比的扫描对,可能存在选择偏倚。
  • 良恶性淋巴结的IC值存在明显重叠,诊断效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aims of this study were to evaluate spectral detector CT (SDCT)-derived iodine concentration (IC) of lymph nodes diagnosed as metastatic and benign in prostate-specific membrane antigen (PSMA) PET/CT and to assess its potential use for lymph node assessment in prostate cancer. PATIENTS AND METHODS: Thirty-four prostate cancer patients were retrospectively included: 16 patients with and 18 without lymph node metastases as determined by PSMA PET/CT. Patients underwent PSMA PET/CT as well as portal venous phase abdominal SDCT for clinical cancer follow-up. Only scan pairs with a stable nodal status indicated by constant size as well as comparable prostate-specific antigen (PSA) levels were included. One hundred benign and 96 suspected metastatic lymph nodes were annotated and correlated between SDCT and PSMA PET/CT. Iodine concentration in SDCT-derived iodine maps and SUVmax in ultra-high definition reconstructions from PSMA PET/CT were acquired based on the region of interest. RESULTS: Metastatic lymph nodes as per PSMA PET/CT showed higher IC than nonmetastatic nodes (1.9 ± 0.6 mg/mL vs 1.5 ± 0.5 mg/mL, P < 0.05) resulting in an AUC of 0.72 and sensitivity/specificity of 81.3%/58.5%. The mean short axis diameter of metastatic lymph nodes was larger than that of nonmetastatic nodes (6.9 ± 3.6 mm vs 5.3 ± 1.3 mm; P < 0.05); a size threshold of 1 cm short axis diameter resulted in a sensitivity/specificity of 12.8%/99.0%. There was a significant yet weak positive correlation between SUVmax and IC (rs = 0.25; P < 0.001). CONCLUSIONS: Spectral detector CT-derived IC was increased in lymph nodes diagnosed as metastatic in PSMA PET/CT yet showed considerable data overlap. The correlation between IC and SUVmax was weak, highlighting the role of PSMA PET/CT as important reference imaging modality for detection of lymph node metastases in prostate cancer patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lennartz S, Täger P, Zopfs D, et al. Lymph Node Assessment in Prostate Cancer: Evaluation of Iodine Quantification With Spectral Detector CT in Correlation to PSMA PET/CT. Clin Nucl Med. 2021. PMID: 33443954. doi:10.1097/RLU.0000000000003496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。